Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cells
- 1 November 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 17 (10), 1163-1169
- https://doi.org/10.1097/01.cad.0000236310.66080.ed
Abstract
In the course of our continuing search for new natural anticancer compounds for treatment and/or prevention of prostate cancer, our laboratory has focused its search on poorly investigated lichen metabolites, sphaerophorin, pannarin and epiphorellic acid-1. To this end, we treated DU-145, a cell line resembling the last stage of prostate carcinoma, with different concentrations (6–50 μmol/l) of these compounds for 72 h. Our data clearly evidenced that these lichen metabolites inhibit the growth of human prostate carcinoma DU-145 cells, but pannarin exhibits a higher effect. Our data show an induction of apoptotic death of advanced prostate cancer cells by sphaerophorin, pannarin and epiphorellic acid-1. In fact, a significant (PKeywords
This publication has 34 references indexed in Scilit:
- Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasiaUrologic Oncology, 2005
- Characterization of Chemical Constituents in Scutellaria baicalensis with Antiandrogenic and Growth-Inhibitory Activities toward Prostate CarcinomaClinical Cancer Research, 2005
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Resveratrol and Propolis as Necrosis or Apoptosis Inducers in Human Prostate Carcinoma CellsOncology Research, 2004
- Cancer chemoprevention with dietary phytochemicalsNature Reviews Cancer, 2003
- The Future of Prostate Cancer PreventionAnnals of the New York Academy of Sciences, 2001
- The development of androgen-independent prostate cancerNature Reviews Cancer, 2001
- Oral etoposide in the treatment of hormone-refractory prostate cancerCancer, 1994
- Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology groupCancer, 1993
- Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancerUrology, 1992